Author(s): Benson JD, Chen YN, CornellKennon SA, Dorsch M, Kim S,
Abstract Share this page
Abstract A cancer drug target is only truly validated by demonstrating that a given therapeutic agent is clinically effective and acts through the target against which it was designed. Nevertheless, it is desirable to declare an early-stage drug target as 'validated' before investing in a full-scale drug discovery programme dedicated to it. Although the outcome of validation studies can guide cancer research programmes, strictly defined universal validation criteria have not been established.
This article was published in Nature
and referenced in Advances in Pharmacoepidemiology and Drug Safety